Cessation or Continuation of Aspirin in Patients Undergoing 20-gauge Pars Plana Vitrectomy due to Diabetic Retinopathy
Authors:
Open Access
- 25 June 2017
- journal article
- Published by Salvia Medical Sciences Ltd in Galen Medical Journal
- Vol. 6 (2)
Abstract
Background: This study aimed to evaluate the incidence of ocular hemorrhages in patients with proliferative diabetic retinopathy (PDR) undergoing 20-gauge pars plana vitrectomy (PPV) taking aspirin as an antiplatelet agent versus those who did not take any aspirin. Materials and Methods: A total of 180 patients (mean age of 60.5 ± 9.9 years) with PDR referred to Baqiyatallah University Hospital in 2016 were enrolled in aspirin and control groups each group containing 90 patients. All participants underwent a standard 20-gauge diabetic PPV. Laboratory data, including fasting blood sugar, prothrombin time, partial thromboplastin, bleeding time, and platelets count, and intraoperative data, including bleeding and its type (retinal, subretinal, vitreous, conjunctival, sub-conjunctival, and hyphema), were collected and analyzed using SPSS16 software. Results: Bleeding occurred in 56 patients. There were no significant differences in the incidence of bleeding between aspirin (33 patients) and control groups (23patients) (P= 0.1). Likewise, no significant differences were observed in the type of bleeding between the two groups (P= 0.11). Age, gender, hypertension, type of operation, and laboratory findings were not significant between patients with and without bleeding. Conclusion: The results of this study indicated that taking aspirin is not associated with a higher risk of post-PPV surgery bleeding in comparison with the control group. Additionally, the type of bleeding did not significantly differ between the two groups. Hence, there is no urgent need for discontinuation of this medication in diabetic patients undergoing PPV.[GMJ.2017;6(2):95-101]Keywords
This publication has 16 references indexed in Scilit:
- Management of antithrombotic therapies in patients scheduled for eye surgeryEuropean Journal of Anaesthesiology, 2013
- ANTICOAGULATION AND CLINICALLY SIGNIFICANT POSTOPERATIVE VITREOUS HEMORRHAGE IN DIABETIC VITRECTOMYRetina, 2011
- Antiplatelet and Anticoagulation Therapy in Vitreoretinal SurgeryAmerican Journal of Ophthalmology, 2011
- Comparison of Hemorrhagic Complications of Warfarin and Clopidogrel Bisulfate in 25-Gauge Vitrectomy versus a Control GroupOphthalmology, 2011
- COMPARISON OF CLINICAL OUTCOMES BETWEEN 23-GAUGE AND 20-GAUGE VITRECTOMY IN PATIENTS WITH PROLIFERATIVE DIABETIC RETINOPATHYRetina, 2010
- VITREOUS HEMORRHAGE AFTER THE 25-GAUGE TRANSCONJUNCTIVAL SUTURELESS VITRECTOMY FOR PROLIFERATIVE DIABETIC RETINOPATHYRetina, 2010
- Medical Consequences of Stopping Anticoagulant Therapy Before Intraocular Surgery or Intravitreal InjectionsRetina, 2007
- ANTICOAGULATION WITH WARFARIN IN VITREORETINAL SURGERYRetina, 2007
- Maintenance of Warfarin Anticoagulation for Patients Undergoing Vitreoretinal SurgeryArchives of Ophthalmology (1950), 2006
- The effects of aspirin and warfarin therapy on haemorrhage in vitreoretinal surgeryActa Ophthalmologica Scandinavica, 2003